NAV

Vebreltinib

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Vebreltinib
DrugBank Accession Number
DB16823
Background

Not Available

Type
Small Molecule
Groups
Investigational
Structure
3D
Similar Structures
Weight
Average: 424.391
Monoisotopic: 424.137177004
Chemical Formula
C20H15F3N8
Synonyms
  • Bozitinib
  • Vebreltinib
External IDs
  • APL-101
  • CBI-3103
  • CBT-101
  • PLB-1001

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
2WZP8A9VFN
CAS number
1440964-89-5
InChI Key
QHXLXUIZUCJRKV-UHFFFAOYSA-N
InChI
InChI=1S/C20H15F3N8/c1-29-9-11-6-14(15(21)7-17(11)27-29)20(22,23)19-26-25-18-5-4-16(28-31(18)19)12-8-24-30(10-12)13-2-3-13/h4-10,13H,2-3H2,1H3
IUPAC Name
5-{[6-(1-cyclopropyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]difluoromethyl}-6-fluoro-2-methyl-2H-indazole
SMILES
CN1C=C2C=C(C(F)=CC2=N1)C(F)(F)C1=NN=C2C=CC(=NN12)C1=CN(N=C1)C1CC1

References

General References
Not Available
ChemSpider
72388443
BindingDB
107096
ChEMBL
CHEMBL4650443

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3Active Not RecruitingTreatmentNon-Small Cell Lung Cancer (NSCLC)1
2RecruitingTreatmentAdenocarcinomas of the Gastroesophageal Junction / Advanced Malignant Neoplasm / Brain Neoplasm / Colon Cancer / EGFR Gene Mutations / Exon 14 Skipping / Gastric Cancer / Glioblastoma Multiforme (GBM) / HGF / Lung Cancer / MET Alteration / MET Amplification / MET Fusion / Non-Small Cell Lung Cancer (NSCLC) / Pancreatic Cancer / Renal Cancer / Solid Tumors / Thyroid Cancer1
2RecruitingTreatmentNon-Small Cell Lung Cancer (NSCLC)1
2, 3Active Not RecruitingTreatmentHigh Grade Glioma: Glioblastoma (GBM)1
1CompletedTreatmentGlioma1
1CompletedTreatmentNon-Small Cell Lung Cancer (NSCLC)1
1RecruitingBasic ScienceBioequivalence1
1Unknown StatusTreatmentSolid Tumors1
1, 2RecruitingTreatmentMetastatic Non-Small Cell Lung Cancer1
1, 2TerminatedTreatmentHepatocellular Carcinoma / Renal Cell Carcinoma (RCC)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.055 mg/mLALOGPS
logP3.58ALOGPS
logP3.29Chemaxon
logS-3.9ALOGPS
pKa (Strongest Basic)1.69Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count5Chemaxon
Hydrogen Donor Count0Chemaxon
Polar Surface Area78.72 Å2Chemaxon
Rotatable Bond Count4Chemaxon
Refractivity139.35 m3·mol-1Chemaxon
Polarizability39.62 Å3Chemaxon
Number of Rings6Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created at July 15, 2022 15:55 / Updated at December 01, 2022 11:30